No Data
No Data
A New Cause for Concern: Theravance Biopharma Adds a New Costs Risk
Theravance Biopharma: A Strong Buy on Underappreciated Cash Flow Potential and Strategic Milestones
Earnings Call Summary | Theravance Biopharma(TBPH.US) Q4 2023 Earnings Conference
The following is a summary of the Theravance Biopharma, Inc. (TBPH) Q4 2023 Earnings Call Transcript:Financial Performance:YUPELRI's net sales growth for the full year of 2023 was 9%, achieving $221 m
Balancing Growth Prospects and Clinical Outcomes: Hold Rating on Theravance Biopharma
Theravance Biopharma Expects Non-GAAP Loss In H1 Of 2024 And Approach Non-GAAP Breakeven In H2 Of 2024; Limited Cash Burn Expected In 2024
Theravance Biopharma Expects Non-GAAP Loss In H1 Of 2024 And Approach Non-GAAP Breakeven In H2 Of 2024; Limited Cash Burn Expected In 2024
Recap: Theravance Biopharma Q4 Earnings
Theravance Biopharma (NASDAQ:TBPH) reported its Q4 earnings results on Monday, February 26, 2024 at 04:05 PM.Here's what investors need to know about the announcement.EarningsTheravance Biopharma miss
No Data